Ni Y - Search Results

1

Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging.

De Saint-Hubert M, Wang H, Devos E, Vunckx K, Zhou L, Reutelingsperger C, Verbruggen A, Mortelmans L, Ni Y, Mottaghy FM. De Saint-Hubert M, et al. Among authors: ni y. Mol Imaging Biol. 2011 Oct;13(5):995-1002. doi: 10.1007/s11307-010-0412-z. Mol Imaging Biol. 2011. PMID: 20848227

2

Necrosis-avid contrast agents: introducing nonporphyrin species.

Ni Y, Cresens E, Adriaens P, Miao Y, Verbeke K, Dymarkowski S, Verbruggen A, Marchall G. Ni Y, et al. Acad Radiol. 2002 May;9 Suppl 1:S98-101. doi: 10.1016/s1076-6332(03)80409-9. Acad Radiol. 2002. PMID: 12019908 No abstract available.

3

Exploring multifunctional features of necrosis avid contrast agents.

Ni Y, Cresens E, Adriaens P, Dymarkowski S, Bogaert J, Zhang H, Bosmans H, Verbruggen A, Marchal G. Ni Y, et al. Acad Radiol. 2002 Aug;9 Suppl 2:S488-90. doi: 10.1016/s1076-6332(03)80272-6. Acad Radiol. 2002. PMID: 12188317 No abstract available.

4

Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity.

Parac-Vogt TN, Kimpe K, Laurent S, Vander Elst L, Burtea C, Chen F, Muller RN, Ni Y, Verbruggen A, Binnemans K. Parac-Vogt TN, et al. Among authors: ni y. Chemistry. 2005 May 6;11(10):3077-86. doi: 10.1002/chem.200401207. Chemistry. 2005. PMID: 15776492

5

Necrosis avid contrast agents: functional similarity versus structural diversity.

Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G. Ni Y, et al. Invest Radiol. 2005 Aug;40(8):526-35. doi: 10.1097/01.rli.0000171811.48991.5a. Invest Radiol. 2005. PMID: 16024991 Review.

6

Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent.

Ni Y, Chen F, Mulier S, Sun X, Yu J, Landuyt W, Marchal G, Verbruggen A. Ni Y, et al. Eur Radiol. 2006 May;16(5):1031-40. doi: 10.1007/s00330-005-0094-0. Epub 2006 Jan 21. Eur Radiol. 2006. PMID: 16429271

7

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent.

Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM. Ni Y, et al. Eur J Nucl Med Mol Imaging. 2006 May;33(5):595-601. doi: 10.1007/s00259-005-0013-2. Epub 2006 Feb 1. Eur J Nucl Med Mol Imaging. 2006. PMID: 16450141

8

Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent.

Fonge H, Jin L, Wang H, Ni Y, Bormans G, Verbruggen A. Fonge H, et al. Among authors: ni y. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4001-5. doi: 10.1016/j.bmcl.2007.04.083. Epub 2007 Apr 30. Bioorg Med Chem Lett. 2007. PMID: 17507220

9

Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor.

Fonge H, Van de Putte M, Huyghe D, Bormans G, Ni Y, de Witte P, Verbruggen A. Fonge H, et al. Among authors: ni y. Contrast Media Mol Imaging. 2007 May-Jun;2(3):113-9. doi: 10.1002/cmmi.136. Contrast Media Mol Imaging. 2007. PMID: 17546702 Free article.

10

Necrosis avidity of (99m)Tc(CO)3-labeled pamoic acid derivatives: synthesis and preliminary biological evaluation in animal models of necrosis.

Fonge H, Chitneni SK, Lixin J, Vunckx K, Prinsen K, Nuyts J, Mortelmans L, Bormans G, Ni Y, Verbruggen A. Fonge H, et al. Among authors: ni y. Bioconjug Chem. 2007 Nov-Dec;18(6):1924-34. doi: 10.1021/bc700236j. Epub 2007 Oct 12. Bioconjug Chem. 2007. PMID: 17929883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,317 results

Search Page

Filters